Prexton Therapeutics’ Parkinson’s Assets First to Emerge from Merck KGAA Restructuring
This article was originally published in The Pink Sheet Daily
Executive Summary
Prexton Therapeutics will be headquartered at the Eclosion incubator facility in Geneva and will advance mGluR compounds for Parkinson’s from the Merck Serono portfolio.
You may also be interested in...
Financings Of The Fortnight: VCs Not Wowed By Single-Asset Company Model
Venture capitalists tell START-UP’s annual survey that seeing will be believing when it comes to the potential of single-asset models. Plus news on recent financings by iPierian, Evotec, ObsEva and Acacia.
Can Merck Serono Bounce Back?
Merck KGAA’s $13 billion acquisition of Serono in 2006 created an unwieldy pharmaceutical organization further hobbled by expensive clinical setbacks. Seven years later, driven by new leadership, it is in the midst of an overdue transformation.
Biopharma Dealmaking Quarterly Statistics, Q3 2012
Q3 2012 biopharma financing, at just over $3 billion, showed a 13% increase over Q2. Follow-on public offerings again were the most prevalent financing type, accounting for a third of these dollars. M&A volume was down to just over $7 billion, compared with Q2’s $35.9 billion and only two Q3 transactions topped the billion-dollar mark. Antibody alliances made up just over a quarter of the total $2.2 billion in deal volume, with 19 deals signed in the area.